Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Puma Biotechnology (PBYI) Other Non Operating Income: 2017-2025

Historic Other Non Operating Income for Puma Biotechnology (PBYI) over the last 8 years, with Sep 2025 value amounting to $115,000.

  • Puma Biotechnology's Other Non Operating Income fell 66.86% to $115,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year decrease of 6.72%. This contributed to the annual value of $862,000 for FY2024, which is 13.57% up from last year.
  • Latest data reveals that Puma Biotechnology reported Other Non Operating Income of $115,000 as of Q3 2025, which was down 71.95% from $410,000 recorded in Q2 2025.
  • In the past 5 years, Puma Biotechnology's Other Non Operating Income ranged from a high of $22.5 million in Q4 2021 and a low of -$204,000 during Q4 2022.
  • For the 3-year period, Puma Biotechnology's Other Non Operating Income averaged around $227,727, with its median value being $156,000 (2024).
  • Data for Puma Biotechnology's Other Non Operating Income shows a peak YoY increase of 414.22% (in 2023) and a maximum YoY decrease of 184.00% (in 2023) over the last 5 years.
  • Puma Biotechnology's Other Non Operating Income (Quarterly) stood at $22.5 million in 2021, then tumbled by 100.91% to -$204,000 in 2022, then surged by 414.22% to $641,000 in 2023, then plummeted by 58.19% to $268,000 in 2024, then crashed by 66.86% to $115,000 in 2025.
  • Its Other Non Operating Income stands at $115,000 for Q3 2025, versus $410,000 for Q2 2025 and $359,000 for Q1 2025.